Roanoke Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $571K | Buy |
2,725
+75
| +3% | +$14.6K | 0.2% | 60 |
|
|
2024
Q4 | $471K | Sell |
2,650
-400
| -13% | -$73.5K | 0.15% | 63 |
|
|
2024
Q3 | $602K | Hold |
3,050
| – | – | 0.19% | 63 |
|
|
2024
Q2 | $523K | Hold |
3,050
| – | – | 0.17% | 64 |
|
|
2024
Q1 | $555K | Hold |
3,050
| – | – | 0.18% | 64 |
|
|
2023
Q4 | $473K | Hold |
3,050
| – | – | 0.18% | 69 |
|
|
2023
Q3 | $455K | Hold |
3,050
| – | – | 0.19% | 71 |
|
|
2023
Q2 | $411K | Hold |
3,050
| – | – | 0.16% | 76 |
|
|
2023
Q1 | $486K | Hold |
3,050
| – | – | 0.21% | 72 |
|
|
2022
Q4 | $493K | Hold |
3,050
| – | – | 0.22% | 72 |
|
|
2022
Q3 | $409K | Hold |
3,050
| – | – | 0.19% | 80 |
|
|
2022
Q2 | $467K | Buy |
3,050
+400
| +15% | +$61.1K | 0.21% | 76 |
|
|
2022
Q1 | $430K | Hold |
2,650
| – | – | 0.16% | 85 |
|
|
2021
Q4 | $359K | Buy |
2,650
+150
| +6% | +$17.7K | 0.12% | 91 |
|
|
2021
Q3 | $270K | Buy |
2,500
+300
| +14% | +$34.3K | 0.1% | 94 |
|
|
2021
Q2 | $248K | Buy |
+2,200
| New | +$248K | 0.09% | 96 |
|
|
2018
Q4 | – | Sell |
-10,086
| Closed | -$954K | – | 103 |
|
|
2018
Q3 | $954K | Hold |
10,086
| – | – | 0.43% | 58 |
|
|
2018
Q2 | $934K | Sell |
10,086
-50
| -0.5% | -$4.88K | 0.45% | 56 |
|
|
2018
Q1 | $959K | Sell |
10,136
-162
| -2% | -$17.8K | 0.46% | 55 |
|
|
2017
Q4 | $996K | Hold |
10,298
| – | – | 0.48% | 55 |
|
|
2017
Q3 | $915K | Buy |
10,298
+85
| +0.8% | +$6.47K | 0.43% | 57 |
|
|
2017
Q2 | $741K | Buy |
10,213
+1,230
| +14% | +$82.7K | 0.35% | 63 |
|
|
2017
Q1 | $585K | Sell |
8,983
-240
| -3% | -$15.1K | 0.28% | 63 |
|
|
2016
Q4 | $578K | Sell |
9,223
-950
| -9% | -$58K | 0.26% | 63 |
|
|
2016
Q3 | $642K | Sell |
10,173
-1,055
| -9% | -$68.3K | 0.29% | 62 |
|
|
2016
Q2 | $695K | Sell |
11,228
-1,525
| -12% | -$92.9K | 0.32% | 60 |
|
|
2016
Q1 | $728K | Sell |
12,753
-22,375
| -64% | -$1.25M | 0.34% | 58 |
|
|
2015
Q4 | $2.08M | Sell |
35,128
-29,108
| -45% | -$1.68M | 0.89% | 41 |
|
|
2015
Q3 | $3.5M | Buy |
64,236
+180
| +0.3% | +$11.7K | 1.28% | 35 |
|
|
2015
Q2 | $4.3M | Buy |
64,056
+36,390
| +132% | +$2.38M | 1.39% | 32 |
|
|
2015
Q1 | $1.62M | Buy |
27,666
+100
| +0.4% | +$6.04K | 0.53% | 53 |
|
|
2014
Q4 | $1.8M | Buy |
27,566
+12,360
| +81% | +$779K | 0.62% | 51 |
|
|
2014
Q3 | $878K | Sell |
15,206
-500
| -3% | -$27.8K | 0.36% | 60 |
|
|
2014
Q2 | $886K | Sell |
15,706
-248
| -2% | -$13K | 0.34% | 62 |
|
|
2014
Q1 | $820K | Hold |
15,954
| – | – | 0.36% | 59 |
|
|
2013
Q4 | $843K | Hold |
15,954
| – | – | 0.39% | 59 |
|
|
2013
Q3 | $763K | Buy |
+15,954
| New | +$707K | 0.37% | 58 |
|
Other funds holding ABBV
Roanoke Asset Management's ABBV Position: Q1 2025 in Review
Roanoke Asset Management increased its AbbVie (ABBV) stake by 2.8% in Q1 2025, buying an estimated $14.6K and bringing the position to 2,725 shares worth $571K. The position accounts for 0.2% of the portfolio, ranked #60.
Roanoke Asset Management first reported a position in ABBV in Q3 2013 and has held it in 37 quarters since. The position peaked at $4.3M in Q2 2015. 3,819 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.
- Roanoke Asset Management held 2,725 shares of AbbVie worth $571K as of Q1 2025.
- Roanoke Asset Management bought 75 AbbVie shares in Q1 2025, an estimated $14.6K.
- AbbVie made up 0.2% of Roanoke Asset Management's portfolio in Q1 2025, its #60 holding.
- Roanoke Asset Management first reported a position in AbbVie in Q3 2013 and has held it in 37 quarters since.
- Roanoke Asset Management's AbbVie position peaked at $4.3M in Q2 2015.
- 3,819 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.
Based on Roanoke Asset Management's 13F filing for Q1 2025, filed 13 May 2025.